Cargando…
Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1
We have recently shown that induction of the p53 tumour suppressor protein by the small-molecule RITA (reactivation of p53 and induction of tumour cell apoptosis; 2,5-bis(5-hydroxymethyl-2-thienyl)furan) inhibits hypoxia-inducible factor-1α and vascular endothelial growth factor expression in vivo a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122121/ https://www.ncbi.nlm.nih.gov/pubmed/21593792 http://dx.doi.org/10.1038/cddis.2011.42 |
_version_ | 1782206899912966144 |
---|---|
author | Ahmed, A Yang, J Maya-Mendoza, A Jackson, D A Ashcroft, M |
author_facet | Ahmed, A Yang, J Maya-Mendoza, A Jackson, D A Ashcroft, M |
author_sort | Ahmed, A |
collection | PubMed |
description | We have recently shown that induction of the p53 tumour suppressor protein by the small-molecule RITA (reactivation of p53 and induction of tumour cell apoptosis; 2,5-bis(5-hydroxymethyl-2-thienyl)furan) inhibits hypoxia-inducible factor-1α and vascular endothelial growth factor expression in vivo and induces p53-dependent tumour cell apoptosis in normoxia and hypoxia. Here, we demonstrate that RITA activates the canonical ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related DNA damage response pathway. Interestingly, phosphorylation of checkpoint kinase (CHK)-1 induced in response to RITA was influenced by p53 status. We found that induction of p53, phosphorylated CHK-1 and γH2AX proteins was significantly increased in S-phase. Furthermore, we found that RITA stalled replication fork elongation, prolonged S-phase progression and induced DNA damage in p53 positive cells. Although CHK-1 knockdown did not significantly affect p53-dependent DNA damage or apoptosis induced by RITA, it did block the ability for DNA integrity to be maintained during the immediate response to RITA. These data reveal the existence of a novel p53-dependent S-phase DNA maintenance checkpoint involving CHK-1. |
format | Online Article Text |
id | pubmed-3122121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-31221212011-07-05 Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1 Ahmed, A Yang, J Maya-Mendoza, A Jackson, D A Ashcroft, M Cell Death Dis Original Article We have recently shown that induction of the p53 tumour suppressor protein by the small-molecule RITA (reactivation of p53 and induction of tumour cell apoptosis; 2,5-bis(5-hydroxymethyl-2-thienyl)furan) inhibits hypoxia-inducible factor-1α and vascular endothelial growth factor expression in vivo and induces p53-dependent tumour cell apoptosis in normoxia and hypoxia. Here, we demonstrate that RITA activates the canonical ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related DNA damage response pathway. Interestingly, phosphorylation of checkpoint kinase (CHK)-1 induced in response to RITA was influenced by p53 status. We found that induction of p53, phosphorylated CHK-1 and γH2AX proteins was significantly increased in S-phase. Furthermore, we found that RITA stalled replication fork elongation, prolonged S-phase progression and induced DNA damage in p53 positive cells. Although CHK-1 knockdown did not significantly affect p53-dependent DNA damage or apoptosis induced by RITA, it did block the ability for DNA integrity to be maintained during the immediate response to RITA. These data reveal the existence of a novel p53-dependent S-phase DNA maintenance checkpoint involving CHK-1. Nature Publishing Group 2011-05 2011-05-19 /pmc/articles/PMC3122121/ /pubmed/21593792 http://dx.doi.org/10.1038/cddis.2011.42 Text en Copyright © 2011 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Original Article Ahmed, A Yang, J Maya-Mendoza, A Jackson, D A Ashcroft, M Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1 |
title | Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1 |
title_full | Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1 |
title_fullStr | Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1 |
title_full_unstemmed | Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1 |
title_short | Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1 |
title_sort | pharmacological activation of a novel p53-dependent s-phase checkpoint involving chk-1 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122121/ https://www.ncbi.nlm.nih.gov/pubmed/21593792 http://dx.doi.org/10.1038/cddis.2011.42 |
work_keys_str_mv | AT ahmeda pharmacologicalactivationofanovelp53dependentsphasecheckpointinvolvingchk1 AT yangj pharmacologicalactivationofanovelp53dependentsphasecheckpointinvolvingchk1 AT mayamendozaa pharmacologicalactivationofanovelp53dependentsphasecheckpointinvolvingchk1 AT jacksonda pharmacologicalactivationofanovelp53dependentsphasecheckpointinvolvingchk1 AT ashcroftm pharmacologicalactivationofanovelp53dependentsphasecheckpointinvolvingchk1 |